Pieris Research Development vs Other Operating Expenses Analysis

PIRS Stock

USD 11.50 0.25 2.22%

Pieris Pharmaceuticals financial indicator trend analysis is much more than just breaking down Pieris Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pieris Pharmaceuticals is a good investment. Please check the relationship between Pieris Pharmaceuticals Research Development and its Other Operating Expenses accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

Research Development vs Other Operating Expenses

Research Development vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pieris Pharmaceuticals Research Development account and Other Operating Expenses. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Pieris Pharmaceuticals' Research Development and Other Operating Expenses is 0.96. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Pieris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Pieris Pharmaceuticals' Research Development and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Pieris Pharmaceuticals are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Research Development i.e., Pieris Pharmaceuticals' Research Development and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pieris Pharmaceuticals. It is also known as Pieris Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from Pieris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pieris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.At this time, Pieris Pharmaceuticals' Issuance Of Capital Stock is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 0.07 in 2024, whereas Selling General Administrative is likely to drop slightly above 13.5 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	31.4M	25.9M	42.8M	25.4M
Depreciation And Amortization	3.7M	8.2M	1.8M	1.9M

Total Revenue Depreciation And Amortization

Pieris Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Retained Earnings Total Equity	Short Term Investments
Total Assets		0.73	0.73	0.91	0.82	-0.9	-0.56	0.92	0.99	0.73	0.81	0.91	0.97	0.97	0.09	0.64	0.9	0.8	0.62	0.74	0.81	0.69	0.55	0.5	-0.71	0.65
Short Long Term Debt Total	0.73		0.58	0.64	0.77	-0.67	-0.65	0.66	0.71	0.86	0.61	0.7	0.64	0.73	0.55	0.78	0.67	0.77	0.53	0.63	0.57	0.6	0.52	0.48	-0.73	0.48
Other Current Liab	0.73	0.58		0.74	0.76	-0.77	-0.81	0.78	0.71	0.85	0.59	0.68	0.64	0.74	-0.1	0.82	0.59	0.77	0.73	0.64	0.71	0.7	0.56	0.21	-0.86	0.28
Total Current Liabilities	0.91	0.64	0.74		0.65	-0.82	-0.61	0.8	0.89	0.69	0.71	0.85	0.93	0.93	0.12	0.62	0.89	0.64	0.48	0.9	0.67	0.59	0.37	0.63	-0.71	0.68
Total Stockholder Equity	0.82	0.77	0.76	0.65		-0.82	-0.68	0.84	0.82	0.78	0.6	0.73	0.67	0.84	0.17	0.76	0.68	1.0	0.66	0.49	0.86	0.65	0.56	0.2	-0.79	0.44
Net Debt	-0.9	-0.67	-0.77	-0.82	-0.82		0.48	-0.98	-0.92	-0.65	-0.73	-0.75	-0.84	-0.89	-0.16	-0.58	-0.75	-0.8	-0.5	-0.63	-0.71	-0.54	-0.46	-0.24	0.65	-0.39
Retained Earnings	-0.56	-0.65	-0.81	-0.61	-0.68	0.48		-0.51	-0.49	-0.89	-0.32	-0.68	-0.46	-0.62	-0.01	-0.93	-0.57	-0.72	-0.82	-0.63	-0.64	-0.82	-0.69	-0.42	0.97	-0.29
Cash	0.92	0.66	0.78	0.8	0.84	-0.98	-0.51		0.93	0.67	0.78	0.78	0.87	0.89	0.09	0.59	0.75	0.81	0.59	0.59	0.76	0.63	0.56	0.23	-0.68	0.36
Cash And Short Term Investments	0.99	0.71	0.71	0.89	0.82	-0.92	-0.49	0.93		0.68	0.78	0.88	0.95	0.97	0.09	0.59	0.9	0.8	0.52	0.74	0.77	0.59	0.46	0.43	-0.65	0.68
Common Stock Total Equity	0.73	0.86	0.85	0.69	0.78	-0.65	-0.89	0.67	0.68		0.56	0.75	0.63	0.73	0.21	0.97	0.66	0.81	0.79	0.71	0.69	0.81	0.66	0.48	-0.93	0.39
Common Stock Shares Outstanding	0.81	0.61	0.59	0.71	0.6	-0.73	-0.32	0.78	0.78	0.56		0.57	0.81	0.71	0.21	0.42	0.55	0.55	0.43	0.44	0.55	0.46	0.42	0.27	-0.51	0.39
Non Current Liabilities Total	0.91	0.7	0.68	0.85	0.73	-0.75	-0.68	0.78	0.88	0.75	0.57		0.9	0.92	-0.05	0.7	0.97	0.74	0.74	0.8	0.79	0.82	0.68	0.61	-0.77	0.68
Total Liab	0.97	0.64	0.64	0.93	0.67	-0.84	-0.46	0.87	0.95	0.63	0.81	0.9		0.93	0.05	0.53	0.91	0.64	0.54	0.77	0.71	0.64	0.49	0.57	-0.62	0.68
Total Current Assets	0.97	0.73	0.74	0.93	0.84	-0.89	-0.62	0.89	0.97	0.73	0.71	0.92	0.93		0.11	0.66	0.93	0.83	0.56	0.8	0.8	0.64	0.48	0.51	-0.74	0.72
Short Term Debt	0.09	0.55	-0.1	0.12	0.17	-0.16	-0.01	0.09	0.09	0.21	0.21	-0.05	0.05	0.11		0.18	0.03	0.16	-0.24	0.16	-0.05	-0.13	-0.21	0.34	-0.08	0.04
Common Stock	0.64	0.78	0.82	0.62	0.76	-0.58	-0.93	0.59	0.59	0.97	0.42	0.7	0.53	0.66	0.18		0.6	0.8	0.78	0.68	0.65	0.79	0.64	0.46	-0.94	0.35
Other Liab	0.9	0.67	0.59	0.89	0.68	-0.75	-0.57	0.75	0.9	0.66	0.55	0.97	0.91	0.93	0.03	0.6		0.67	0.56	0.85	0.71	0.67	0.52	0.65	-0.67	0.78
Net Tangible Assets	0.8	0.77	0.77	0.64	1.0	-0.8	-0.72	0.81	0.8	0.81	0.55	0.74	0.64	0.83	0.16	0.8	0.67		0.68	0.5	0.86	0.67	0.57	0.22	-0.82	0.43
Property Plant And Equipment Net	0.62	0.53	0.73	0.48	0.66	-0.5	-0.82	0.59	0.52	0.79	0.43	0.74	0.54	0.56	-0.24	0.78	0.56	0.68		0.41	0.74	0.97	0.91	0.3	-0.85	0.16
Current Deferred Revenue	0.74	0.63	0.64	0.9	0.49	-0.63	-0.63	0.59	0.74	0.71	0.44	0.8	0.77	0.8	0.16	0.68	0.85	0.5	0.41		0.46	0.54	0.31	0.75	-0.67	0.7
Accounts Payable	0.81	0.57	0.71	0.67	0.86	-0.71	-0.64	0.76	0.77	0.69	0.55	0.79	0.71	0.8	-0.05	0.65	0.71	0.86	0.74	0.46		0.76	0.53	0.38	-0.73	0.46
Non Current Assets Total	0.69	0.6	0.7	0.59	0.65	-0.54	-0.82	0.63	0.59	0.81	0.46	0.82	0.64	0.64	-0.13	0.79	0.67	0.67	0.97	0.54	0.76		0.88	0.49	-0.86	0.26
Other Assets	0.55	0.52	0.56	0.37	0.56	-0.46	-0.69	0.56	0.46	0.66	0.42	0.68	0.49	0.48	-0.21	0.64	0.52	0.57	0.91	0.31	0.53	0.88		0.15	-0.74	0.07
Net Receivables	0.5	0.48	0.21	0.63	0.2	-0.24	-0.42	0.23	0.43	0.48	0.27	0.61	0.57	0.51	0.34	0.46	0.65	0.22	0.3	0.75	0.38	0.49	0.15		-0.43	0.61
Retained Earnings Total Equity	-0.71	-0.73	-0.86	-0.71	-0.79	0.65	0.97	-0.68	-0.65	-0.93	-0.51	-0.77	-0.62	-0.74	-0.08	-0.94	-0.67	-0.82	-0.85	-0.67	-0.73	-0.86	-0.74	-0.43		-0.34
Short Term Investments	0.65	0.48	0.28	0.68	0.44	-0.39	-0.29	0.36	0.68	0.39	0.39	0.68	0.68	0.72	0.04	0.35	0.78	0.43	0.16	0.7	0.46	0.26	0.07	0.61	-0.34

Click cells to compare fundamentals

Pieris Pharmaceuticals Account Relationship Matchups

Pieris Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Other Current Liab	5.0M	5.5M	15.8M	10.7M	8.6M	5.7M
Total Current Liabilities	27.0M	22.1M	50.6M	36.6M	11.9M	23.7M
Total Stockholder Equity	51.4M	31.0M	50.8M	27.9M	26.8M	28.8M
Net Debt	(46.0M)	(53.5M)	(103.9M)	(25.5M)	(17.4M)	(18.3M)
Retained Earnings	(174.2M)	(211.4M)	(257.1M)	(290.4M)	(315.0M)	(299.2M)
Cash	62.3M	70.4M	117.8M	38.6M	17.4M	16.5M
Cash And Short Term Investments	104.2M	70.4M	117.8M	59.2M	26.4M	25.0M
Common Stock Total Equity	54K	55K	56K	72K	82.8K	42.7K
Common Stock Shares Outstanding	50.6M	54.5M	64.5M	74.2M	1.1M	1.1M
Liabilities And Stockholders Equity	141.1M	105.0M	153.6M	95.5M	38.7M	36.7M
Non Current Liabilities Total	62.7M	51.8M	52.2M	31.0M	35.6M	30.4M
Total Liab	89.7M	74.0M	102.8M	67.6M	11.9M	11.3M
Total Current Assets	115.0M	75.7M	127.6M	73.4M	38.7M	68.3M
Common Stock	55K	56K	72K	74K	98K	53.4K
Other Liab	47.3M	35.9M	38.4M	18.7M	21.5M	26.7M
Net Tangible Assets	51.4M	31.0M	50.8M	27.9M	32.1M	31.6M
Property Plant And Equipment Net	22.9M	26.0M	23.0M	20.7M	23.8M	12.2M
Current Deferred Revenue	11.3M	12.6M	25.1M	20.8M	23.9M	17.9M
Accounts Payable	10.1M	3.0M	8.6M	4.2M	3.4M	4.0M
Non Current Assets Total	26.1M	29.3M	25.9M	22.1M	25.4M	14.6M
Other Assets	910K	3.1M	7.2M	2.9M	3.3M	1.8M
Net Receivables	6.8M	1.7M	3.3M	5.8M	6.0M	4.4M
Retained Earnings Total Equity	(147.1M)	(174.2M)	(211.4M)	(257.1M)	(231.4M)	(219.9M)
Short Term Investments	34.8M	53.2M	41.9M	20.5M	9.0M	15.9M
Capital Surpluse	189.9M	227.5M	242.7M	307.0M	353.0M	370.7M
Other Current Assets	4.1M	3.6M	6.5M	8.4M	6.3M	4.3M
Other Stockholder Equity	227.5M	242.7M	307.0M	318.5M	341.6M	214.7M
Property Plant And Equipment Gross	22.9M	22.0M	23.0M	20.7M	23.8M	25.0M
Accumulated Other Comprehensive Income	(2.0M)	(295K)	829K	(254K)	28K	29.4K
Non Current Liabilities Other	27K	62.7M	6K	52.2M	60.1M	63.1M
Property Plant Equipment	19.5M	26.0M	23.0M	20.7M	23.8M	25.0M
Non Currrent Assets Other	3.1M	3.3M	2.9M	1.4M	1.6M	1.7M
Net Invested Capital	51.4M	31.0M	50.8M	27.9M	32.1M	39.0M
Net Working Capital	88.0M	53.6M	77.1M	36.8M	33.2M	51.6M
Capital Stock	55K	56K	72K	74K	85.1K	68.4K

Pair Trading with Pieris Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pieris Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Pieris Stock

0.71

Equillium Earnings Call This Week

Pair Corr

Moving against Pieris Stock

0.69	ELYM	Eliem Therapeutics	Pair Corr
0.48	MRK	Merck Company Financial Report 6th of August 2024	Pair Corr

The ability to find closely correlated positions to Pieris Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pieris Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pieris Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pieris Pharmaceuticals to buy it.

The correlation of Pieris Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pieris Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pieris Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Pieris Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Pieris Pharmaceuticals is a strong investment it is important to analyze Pieris Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pieris Pharmaceuticals' future performance. For an informed investment choice regarding Pieris Stock, refer to the following important reports:

How To Invest In Pieris

Details

Is Pieris Stock a good investment?

Details

What is Pieris Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pieris Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pieris Stock please use our How to Invest in Pieris Pharmaceuticals guide.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Pieris Stock analysis

When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format

Is Pieris Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pieris Pharmaceuticals. If investors know Pieris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pieris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(21.60)

Revenue Per Share

38.026

Quarterly Revenue Growth

(0.78)

Return On Assets

(0.15)

Return On Equity

(0.90)

The market value of Pieris Pharmaceuticals is measured differently than its book value, which is the value of Pieris that is recorded on the company's balance sheet. Investors also form their own opinion of Pieris Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pieris Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pieris Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pieris Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pieris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pieris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pieris Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pieris Research Development vs Other Operating Expenses Analysis

Research Development vs Other Operating Expenses

Research Development vs Other Operating Expenses Correlation Analysis

Correlation Coefficient

Research Development

Other Operating Expenses

Pieris Pharmaceuticals fundamental ratios Correlations

Pieris Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pieris Pharmaceuticals fundamental ratios Accounts

Pair Trading with Pieris Pharmaceuticals

Moving together with Pieris Stock

Moving against Pieris Stock

Complementary Tools for Pieris Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Assets
Total Liab	+ 0.97	Total Assets
Total Current Assets	+ 0.97	Total Assets
Retained Earnings Total Equity	+ 0.97	Retained Earnings
Total Current Assets	+ 0.97	Cash And Short Term Investments

Cash	- 0.98	Net Debt
Retained Earnings Total Equity	- 0.94	Common Stock
Retained Earnings Total Equity	- 0.93	Common Stock Total Equity
Common Stock	- 0.93	Retained Earnings
Cash And Short Term Investments	- 0.92	Net Debt
Net Debt	- 0.9	Total Assets